GSK PLC
GSK: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 5,275.00 | Hrhh | Jrkwpfjpq |
Undervalued GSK Posts Strong Q4 as Wide Portfolio Sets Up Steady Growth Outlook
GSK reported fourth-quarter results and provided 2023 guidance that ran slightly above our expectations, but we don't expect any major changes to our GSK fair value estimate based on the update. We continue to view the stock as undervalued, with the market likely overly concerned about Zantac litigation and not appreciating GSK’s steady growth outlook, which also supports its wide moat.